simlukafusp alfa + Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody + Gemcitabine + Vinorelbine
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers
Conditions
Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers
Trial Timeline
Feb 19, 2018 → Dec 30, 2021
NCT ID
NCT03386721About simlukafusp alfa + Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody + Gemcitabine + Vinorelbine
simlukafusp alfa + Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody + Gemcitabine + Vinorelbine is a phase 2 stage product being developed by Roche for Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers. The current trial status is terminated. This product is registered under clinical trial identifier NCT03386721. Target conditions include Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03386721 | Phase 2 | Terminated |
Competing Products
20 competing products in Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers